Your target's healthcare costs hide $2-4M in phantom spread. Post-close teams can't find it. Buyers discount your exit claims. Evidence-backed diligence changes everything.
Traditional diligence misses hidden healthcare spreads, creating post-close surprises that evaporate EBITDA and crater exit multiples
From data upload to management presentation in under 2 days. Evidence-backed findings, normalized EBITDA model, and post-close playbook included.
Secure upload of pharmacy claims, PBM contract, census, and plan design documents into isolated diligence workspace
AI-driven analysis surfaces hidden spreads, benchmarks claims against NADAC, identifies contract leakage, and generates risk heat maps
SiriusB iQ team validates findings, builds normalized EBITDA model, and creates board-ready evidence package with recovery scenarios
Live walkthrough with deal team covering findings, value at-risk, quick wins, and post-close governance framework recommendation
Post-close value office tools that ensure every synergy has an owner, every claim has evidence, and every board pack has audit-grade receipts
Portfolio-wide dashboard tracking healthcare costs, realization status, and governance compliance across all holdings with real-time alerts
Owner-assigned synergy tracking with weekly reconciliation workflows, evidence receipt generation, and automated variance alerting
Continuous monitoring of PBM contract performance vs. guarantees with automated breach detection and recovery workflow initiation
Real-time comparison of pharmacy costs against NADAC, peer portfolios, and Mark Cuban Cost Plus pricing with immediate outlier flagging
AI-powered analysis surfaces immediate value opportunities with pre-built evidence packs and implementation playbooks for rapid deployment
Automated creation of buyer-ready evidence packages documenting all value creation with audit-grade receipts and governance framework handoff
Mid-market PE firm with 8 portfolio companies deploys SiriusB iQ value office across holdings
Healthcare costs tracked as single line item across all 8 companies. Zero visibility into actual spend components.
100-day plans promised "$12M in pharmacy optimization" but no owners, no tracking, no evidence.
CFO admits to IC: "We think we saved money but can't prove it. PBM won't share real data."
Exit buyer discounts optimization claims by 90%. Lost $31M in valuation premium.
Portfolio-wide dashboard shows real-time pharmacy costs vs. NADAC benchmarks across all holdings.
$8.8M in documented savings across 8 companies with 285 evidence receipts per year per holding.
Every synergy has owner, status, and proof. Weekly 15min reconciliation per portfolio company.
Exit buyer adopts governance framework. Pays $37M premium for "audit-ready value creation discipline."
Buyers pay premium for documented governance discipline. Evidence receipts convert PowerPoint claims into measurable alpha.
Evidence-backed diligence, controlled value realization, and audit-ready governance deliver measurable alpha
Evidence-backed diligence playbook, normalized EBITDA template, and post-close value office framework
Schedule a 48-hour diligence sprint briefing and see how evidence-backed healthcare analysis transforms deal confidence